DataMeds AI, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $21.9 million, 94% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
|---|---|---|---|
| Revenue |
8
|
23
|
18
|
| Product |
4
share 49.2%
|
22
+23.8%
share 93.7%
|
18
share 97.5%
|
| Pharmacy Retail Sales |
3
+579.3%
share 42.4%
|
1
+145.7%
share 3.7%
|
0
share 1.9%
|
| Third Party Logistics Services |
1
share 8.5%
|
1
+463.9%
share 2.6%
|
0
share 0.6%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- MEDS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Tampa, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2030763
- Former names
- Wellgistics Health, Inc. (until Jul 21, 2026); Danam Health, Inc (until Sep 27, 2024)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- Cellyan Biotechnology Co., Ltd HKPD
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.